Drug Profile
Eribulin liposomal - Eisai
Alternative Names: E7389 liposomal; E7389-LF; Halaven; Liposomal eribulin - EisaiLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eisai Inc
- Developer Eisai Inc; Ono Pharmaceutical
- Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
- Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 20 Oct 2023 Efficacy and adverse events data from a phase I trial in Gastric cancer presented at 48th European Society for Medical Oncology Congress (ESMO-2023)
- 20 Jun 2023 Phase-I development is ongoing for Solid tumours (Monotherapy) in Japan and United Kingdom (Eisai pipeline, June 2023)
- 02 Jun 2023 Updated efficacy, safety and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)